These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35983667)

  • 1. Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?
    Huqi A; Zoccali C; Giugliano RP; De Caterina R
    Eur Heart J; 2023 Jan; 44(4):322-325. PubMed ID: 35983667
    [No Abstract]   [Full Text] [Related]  

  • 2. Warfarin compared with non-vitamin K antagonist oral anticoagulants in subjects with liver disease and atrial fibrillation: A meta-analysis.
    Su T; Fu Z; Nie Z; Guo D
    Int J Clin Pract; 2021 Oct; 75(10):e14585. PubMed ID: 34192400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants.
    Turagam MK; Velagapudi P; Flaker GC
    Clin Interv Aging; 2015; 10():1431-44. PubMed ID: 26366064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comments on efficacy and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and diabetes mellitus.
    Murat S; Murat B; Gorenek B
    Acta Cardiol; 2021 Nov; 76(9):1041. PubMed ID: 33635173
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in very elderly patients with atrial fibrillation: a single-center experience.
    Weronska A; Broniatowska E; Papuga-Szela E; Undas A
    Kardiol Pol; 2020 Feb; 78(2):154-157. PubMed ID: 32108756
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study).
    Saji N; Kimura K; Tateishi Y; Fujimoto S; Kaneko N; Urabe T; Tsujino A; Iguchi Y;
    J Thromb Thrombolysis; 2016 Nov; 42(4):453-62. PubMed ID: 27207691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 10. Heartbeat: bleeding risk in atrial fibrillation patients on non-vitamin K oral anticoagulant medications.
    Otto CM
    Heart; 2022 Feb; 108(4):243-245. PubMed ID: 35091457
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation.
    Cha MJ; Choi EK; Han KD; Lee SR; Lim WH; Oh S; Lip GYH
    Stroke; 2017 Nov; 48(11):3040-3048. PubMed ID: 28974629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
    Renda G; di Nicola M; De Caterina R
    Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New oral anticoagulants in elderly patients with atrial fibrillation.
    Deedwania PC
    Am J Med; 2013 Apr; 126(4):289-96. PubMed ID: 23369212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K oral anticoagulants as first-line regimen for acute ischemic stroke with non-valvular atrial fibrillation.
    Park CW; Nam HS; Heo JH; Park HJ; Choi JK; Lee HS; Na HK; Kim YD
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105025. PubMed ID: 32807440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study.
    Himmler S; Müller M; Ostwald D; Seddik A; Basic E; Hradetzky E
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):223-230. PubMed ID: 30295561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants with Warfarin in Atrial Fibrillation Patients with a History of Bleeding: A Systematic Review and Meta-Analysis.
    Suah BH; Lee ZY; Teo YH; Teo YN; Syn NLX; Soh RYH; Yeo LLL; Tan BYQ; Ho JS; Li TYW; Lee CH; Chan MY; Yeo TC; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):511-521. PubMed ID: 35292921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study.
    Wang CL; Wu VC; Huang YT; Kuo CF; Chu PH; Chen YL; Wen MS; Chang SH
    J Am Heart Assoc; 2019 May; 8(9):e012029. PubMed ID: 31020896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.